Objectives: The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear.
Introduction
The introduction of potent antiretroviral agents into clinical practice has resulted in a marked improvement of survival in HIV-infected subjects, following the suppression of HIV replication and the consequent recovery of the immune functions. [1] [2] [3] [4] However, numerous patients discontinue antiretroviral treatment due to the development of drug-related side effects or virological failure, with persistent HIV replication. 5 Therapeutic management of such patients is of particular concern to avoid the accumulation of drug mutations, which can reduce HIV susceptibility to the currently available antiretroviral agents. Lopinavir is a potent protease inhibitor (PI) co-formulated with a low dose of ritonavir (lopinavir/ritonavir), which inhibits the 3A4 isoenzyme of cytochrome P 450 leading to higher plasma lopinavir levels. 6 The resulting mean trough concentrations of lopinavir are at least 75 times as high as the protein-binding corrected IC 50 (concentration required to inhibit 50% of replication in vitro) for wild-type HIV. 7 Its potency is due to these high in vivo plasma concentrations and the fact that it provides a high genetic barrier: this latter characteristic means that viruses with up to five mutations associated with lopinavir resistance remain susceptible to the drug, those with six or seven mutations are intermediately susceptible, and only those with more than eight mutations are considered resistant. 8, 9 Current guidelines suggest the use of lopinavir/ritonavir in both naive and heavily pretreated patients.
10,11 Despite numerous reports regarding the efficacy of lopinavir/ritonavir-containing regimens, 12 -16 few data are available about long-term virological efficacy in HIV-infected patients failing a first-line PI-based regimen. This report describes the virological outcome in such HIV-infected patients.
Materials and methods
In our study, during December 2000-December 2002, we included 111 HIV-infected consecutive patients starting lopinavir/ritonavircontaining highly active antiretroviral therapy (HAART). The patients, from five Italian centres for Infectious Diseases, had failed a first-line PI-based HAART. All the patients had plasma HIV RNA viraemia >3 log 10 copies/mL at the time of lopinavir/ritonavir initiation.
Their demographic characteristics, plasma HIV levels and CD4+ cell counts at baseline were recorded, as were data concerning metabolic parameters (total serum cholesterol, serum triglycerides and serum glucose, all obtained under fasting conditions) and their previous antiretroviral treatments. In accordance with our usual clinical practice, HIV RNA measurements were performed at baseline and then every 3 months using the branched chain DNA (b-DNA) technique (Chiron, Inc., detection limit 50 copies/mL). CD4+ cell counts were performed at the same time-points using the Elite flow cytometer (Coulter Corporation, Miami, FL, USA).
We defined virological success as the achievement of two consecutive HIV RNA measurements of <50 copies/mL during followup. Immunological outcome and serum lipid increase were also evaluated, as were the reasons for lopinavir/ritonavir discontinuation and drug-related side effects.
Statistical analysis
The changes in CD4+ cell counts and HIV RNA levels during follow-up were evaluated by t-test. The survival analyses were performed using both an intention-to-treat (ITT) approach and an on-treatment (OT) approach. In the analyses, the time to virological success was defined as the time needed to obtain two consecutive measurements of HIV RNA <50 copies/mL. The Kaplan -Meier method and log-rank test were used to estimate the time-dependent probability of reaching such end-points.
The SPSS 11.0 for Windows 98 statistical software package was used for all of the analyses.
Results
The study involved 111 HIV-infected patients (76.6% male), 47.7% of whom were in CDC stage C. The median age was 38 years (range 22 -75). Fifty-two patients (46.8%) had a CD4+ cell count of <200 cells/mm 3 at baseline. The median CD4+ count was 212 cells/mm 3 (range 1-769), and the median HIV RNA plasma level was 4.36 log 10 copies/mL (range 3.08 -6.34). The median duration of the previous PI-based regimen was 603 days (range 65 -1815). Previous HAART was discontinued because of virological failure by all the patients; in particular, 93 (83.8%) failed a PI plus two nucleoside reverse transcriptase inhibitors (NRTIs)-based HAART and 18 (16.2%) failed a PI plus an NRTI plus a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART before lopinavir/ritonavir initiation ( Table 1) .
Eighty-seven (78.4%) patients received lopinavir/ritonavir plus 2-3 NRTIs, 20 (18.0%) added an NRTI and an NNRTI and four added two NRTIs and a PI (3.6%) according to the genotypic resistance test performed at the time of virological failure (Table 2) .
During a median follow-up of 996 days (range 562-1302), using an ITT approach, median HIV RNA levels progressively decreased, to <50 copies/mL starting from month 3 (baseline versus month 3: P = 0.0001; baseline versus month 12: P = 0.0001) throughout the observation. The percentage of patients with undetectable HIV RNA during follow-up is shown in Figure 1 . By the OT approach the virological outcome was comparable.
ITT analysis showed that 96 patients (86.5%) obtained virological success; the Kaplan -Meier estimate of the probability of such an end-point was 78.4% (95% CI: 70.8 -86.0%) at month 12 and 85.8% (95% CI: 79.3-92.3%) at month 24. These results were also confirmed by OT analysis.
The median CD4+ cell count steadily increased during all the study visits. The median increase was 118 cells/mm 3 ( ± 67) from baseline to month 12 and 153 cells/mm 3 ( ± 30) to month 24. Among 94 patients still on study at month 24, 81 (86.2%) had ZDV+3TC+NFV  16  d4T+3TC+IDV  13  d4T+NVP+NFV  13  d4T+3TC+NFV  8  ZDV+3TC+SQV  7  d4T+3TC+SQV  7  ABC+3TC+IDV  5  d4T+ddI+NFV  5  ddI+3TC+NFV  4  ZDV+ddC+IDV  3  d4T+NVP+IDV  3  d4T+ddI+IDV  2  ddI+EFV+SQV  1  ZDV+ddI+NFV  1  d4T+NVP+SQV  1 ZDV, zidovudine; 3TC, lamivudine; d4T, stavudine; ddI, didanosine; ABC, abacavir; ddC, zalcitabine; NVP, nevirapine; EFV, efavirenz; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir; APV, amprenavir a CD4+ cell count >200 cells/mm 3 with 51 (54.3%) having a CD4+ cell count >350 cells/mm 3 . The remaining 13 patients had a median CD4 cell count of 136 cells/mm 3 (range 49 -199). Thirty-one patients (27.9%) discontinued lopinavir/ritonavir after a median of 670 days (range 142-1066): 16 because of toxicity (eight hyperlipidaemia, seven gastrointestinal intolerance, one hepatic failure), six for HAART simplification, five because of virological failure, one patient was lost at follow-up and three patients died (two owing to Pneumocystis carinii pneumonia and one owing to peritonitis). Gastrointestinal intolerance (including nausea, diarrhoea, vomiting and abnormal stools) was the most common adverse event of mild/moderate intensity: 72 patients reported such an adverse event without discontinuing lopinavir/ritonavir. Other adverse events (including headache, asthenia, abdominal meteorism and abdominal discomfort) were reported less often. Four AIDS-defining events were recorded among our patients: three cases of P. carinii pneumonia (two of these patients died) and one case of oesophageal candidiasis.
At lopinavir/ritonavir initiation, elevations in serum triglycerides (>750 mg/dL) and total cholesterol (>300 mg/dL) classified as grade 3 or greater according to NCAP definition, 17 were observed in one and two patients, respectively. At month 12, four patients (3.6%) had grade 3 triglyceride levels and five patients (4.5%) had grade 3 total cholesterol elevations; at month 24, three patients (3.2%) and two patients (2.1%), respectively, had grade 3 triglyceride and total cholesterol abnormalities. A significant increase was observed for mean values of triglycerides and total cholesterol from baseline to month 3 (+107 mg/dL and +28 mg/dL, respectively); afterwards, such parameters were stable throughout the study. Sixty-three patients (56.8%) had triglycerides <180 mg/dL at lopinavir/ritonavir initiation, compared with 26 (23.4%) at month 12 and with 13 (13.8%) at month 24; 77 patients (69.4%) had total cholesterol <190 mg/dL at lopinavir/ritonavir initiation compared with 47 (42.3%) at month 12 and with 30 (31.9%) at month 24. Fifty patients (45.0%) started a lipid-lowering drug during lopinavir/ritonavir treatment, 38 were prescribed fibrates (including fenofibrates or gemfibrozil) and 12 were prescribed statins (pravastatin). No patient had been treated for hyperlipidaemia before lopinavir/ritonavir initiation. At month 6, patients taking a lipidlowering drug had mean triglycerides and cholesterol levels of 458 mg/dL (SD ± 244) and 234 mg/dL (SD ± 42), respectively. Lipid parameters showed a slight but not significant decrease during observation among these patients: at month 12, triglycerides and cholesterol levels were 408 mg/dL (SD ± 191) and 212 mg/dL (SD ± 47) and at month 24 were 382 mg/dL (SD ± 181) and 202 mg/dL (SD ± 32), respectively.
Among the 15 patients not reaching virological success, eight (53.3%) discontinued lopinavir/ritonavir: five for persistence of detectable serum levels of HIV RNA and three for gastrointestinal intolerance. Genotypic analysis of viral isolates of these patients performed during the observation are summarized in Table 3 . All patients not reaching virological success but discontinuing lopinavir/ritonavir for reasons other than toxicity had at least six mutations in the protease region at positions known to reduce lopinavir/ritonavir susceptibility (L10I/F/R/V, K20M/R, L24I, V32I, L33F, M46I/L, I47V, I50V, F53L, I54V/L, L63P, A71V/T, G73S, V82A/F/T/S, I84V and L90M). 18 Their antiretroviral regimen was modified according to the genotypic test, but none of them achieved HIV RNA <50 copies/mL after HAART modification. Only one patient discontinuing lopinavir/ritonavir for reasons other than virological failure and four continuing lopinavir/ritonavir without virological success developed mutations in the protease region, but all of them had less than five mutations (Table 3) . However, patients discontinuing lopinavir/ritonavir without reaching virological success had a substantial benefit with regard to CD4+ cells, increasing from 197 cells/mm 3 at baseline to 259 cells/mm 3 at discontinuation (P < 0.01).
Conclusions
In this observational study, the use of lopinavir/ritonavir in HIV-infected subjects failing a first-line PI-based HAART led to virological success (defined as at least two consecutive measurements of HIV RNA < 50 copies/mL) in most patients: ITT analysis revealed a 78.4% probability of success after 12 months of treatment and an 85.8% probability of success after 24 months of treatment. This finding in a clinical setting confirms the high potency of lopinavir/ritonavir already reported by other trials. 11 -15 Among patients not achieving virological success, five had a genotypic test showing >5 mutations known to reduce HIV susceptibility to lopinavir/ritonavir. Four patients continued lopinavir/ritonavir-containing HAART despite the presence of < _ 5 mutations in the protease region, according to published data. 8, 13 We also observed a progressive increase in CD4 cell counts, with a significant improvement in immunological condition. Also, patients not reaching virological success had a substantial improvement in their immunological condition; this finding can explain the maintenance of a failing regimen in such a population.
Among 31 patients discontinuing lopinavir/ritonavir, 16 developed drug-related toxicities, mainly gastro-intestinal and metabolic. Several patients reported gastro intolerance, but only seven discontinued lopinavir/ritonavir for this reason. More than two-thirds of patients developed triglyceride or cholesterol elevation during lopinavir/ritonavir-containing HAART; however, only a few of them experienced a grade 3 or greater metabolic toxicity, suggesting that this adverse event was of moderate grade. Fifty patients started a fibrate or a statin: the use of lipid-lowering drugs does not seem to be associated with a significant reduction of these abnormalities, as suggested by other published findings. 19, 20 The limitations of our study are mainly due to its observational nature, so that definitive conclusions cannot be drawn; however, at the moment controlled trials on long-term efficacy and tolerability of PI-containing salvage HAART are rarely performed. 21 Nevertheless, our results confirm, in a clinical setting, that lopinavir/ritonavir is a valid option for the treatment of PI-experienced HIV-infected patients. Prospective studies are required better to assess the effectiveness and good tolerability of this compound in clinical practice. 
